Company news
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) news
Every Verrica Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
September 10, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment o...
August 27, 2026
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 6, 2026
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
August 6, 2026
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for...
July 21, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluatin...
June 22, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
May 12, 2026
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Trea...
May 5, 2026
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
May 5, 2026
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment...
April 9, 2026
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 11, 2026
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
March 5, 2026
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
February 12, 2026
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 9, 2026
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
January 7, 2026
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
November 24, 2025
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 14, 2025
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immun...
November 10, 2025
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to...
October 20, 2025
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immuno...
October 7, 2025
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the...
September 19, 2025
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 12, 2025
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
August 6, 2025
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
July 9, 2025
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Pha...
July 1, 2025
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 28, 2025
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
May 7, 2025
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
April 30, 2025
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
April 7, 2025
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
April 2, 2025
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
March 26, 2025
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
March 3, 2025
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
February 25, 2025
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatmen...
January 21, 2025
Verrica Provides Business and Operational Update
December 20, 2024
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 9, 2024
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Mol...
December 6, 2024
Verrica Announces Pricing of $42.0 Million Public Offering
November 21, 2024
Verrica Announces Proposed Public Offering
November 20, 2024
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
November 4, 2024